

CITATION REPORT

List of articles citing

Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer

DOI: 10.1097/ftd.00000000000000552
Therapeutic Drug Monitoring, 2018, 40, 699-704.

Source: <https://exaly.com/paper-pdf/70997833/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Extrapolation of pharmacokinetic interaction data of proton pump inhibitors obtained in healthy subjects for oral targeted therapies in cancer patients. <i>International Journal of Pharmacokinetics</i> , 2018 , 3, 93-97	0.3	
19	Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 130, 10-17	5.9	66
18	Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 172, 175-182	3.5	4
17	Proton pump inhibitors: placing putative adverse effects in proper perspective. <i>Current Opinion in Gastroenterology</i> , 2019 , 35, 509-516	3	6
16	Proton pump inhibitors: misconceptions and proper prescribing practice. <i>Current Opinion in Gastroenterology</i> , 2020 , 36, 493-500	3	2
15	Administration of erlotinib in apple juice overcomes decreased absorption in a rat model of gastric acid suppression. <i>Drug Metabolism and Pharmacokinetics</i> , 2020 , 35, 534-538	2.2	
14	Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. <i>Clinical Therapeutics</i> , 2020 , 42, 1302-1316	3.5	2
13	A novel architecture for achieving high drug loading in amorphous spray dried dispersion tablets. <i>International Journal of Pharmaceutics: X</i> , 2020 , 2, 100042	3.2	10
12	Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	10
11	Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. <i>Archives of Medical Research</i> , 2021 , 52, 261-269	6.6	6
10	Controversial link between proton pump inhibitors and anticancer agents: review of the literature. <i>Tumori</i> , 2021 , 3008916211025091	1.7	2
9	Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3567-3581	4.4	0
8	The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 2693-2697	4.9	5
7	Concomitant Gastric Acid Suppressants on the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis. <i>International Journal of Clinical Practice</i> , 2022 , 2022, 1-14	2.9	0
6	Proton Pump Inhibitors and Cancer: Current State of Play.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 798272	5.6	0
5	An update on drug-drug interactions associated with proton pump inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 1-10	5.5	0
4	Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study.		

- 3 Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study. ○
- 2 The status of TKI/acid-suppressant concomitant use in 44 hospitals in China: A cross-sectional descriptive study. **2022**, 101, e31770 ○
- 1 Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?. **2023**, 59, 557 ○